Tashkent Medical Academy; Tashkent, Uzbekistan.
*Corresponding author: Ashot D. Dadamov, PhD, Department of Operational Dentistry, Tashkent Medical Academy. 2, Faroby str., 100109, Tashkent, Uzbekistan Tel: 998-71-2894378, 998-93-5853739
Maxillofacial area with its features of the autonomic innervations, rich blood supply and wide spreading of the glandular secreting structures has a specificity of reactions in response to conduct such treatments as radio- and chemotherapy. The use of radio- and chemotherapy to treat maxillofacial carcinoma is discussed in this review.
1. Vineis P, Perera F. Molecular epidemiology and biomarkers in etiologic cancer research: the new in light of the old. Cancer Epidemiol Biomarkers Prev 2007; 16: 1954-1965.
2. Lassau N, Lamuraglia M, Koscienly S. Prognostic value of angiogenesis evaluated with high-frequency and color Doppler sonography for preoperative assessment of primary cutaneous melanomas: correlation with recurrence after a 5 year follow-up period. Cancer Imaging 2006; 6: 24-29.
3. Okada Y, Ueno H, Katagiri M, Shimomura K, et al. Experimental study of antiangiogenic gene therapy targeting VEGF in oral cancer. Odontology 2010; 98(1): 52-59.
4. Vogt U, Brandt B, Krieg R. Indivicon, ein Ansatz zur qualifizierten individualisierten komplementaren Onkologie. Haematopoiesis Immunology 2007; 4:208-216.
5. Hoekstra JW, Kummer JA, van Es R.J. Late (>5 years) regional lymph node metastasis of oral squamous cell carcinoma (SCC), proven by p53 mutation analysis. J Craniomaxillofac Surg 2008; 36:415-418.
6. Zachary T, Kornbluth S, Kornbluth Sc. The apoptosome: Physiological Developmental and Pathological Modes of Regulation. Developmental Cell 2006; 10(5): 549-561.
7. Wang J, Chun H, Wong W, Spenser D, Lenardo J. Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA 2001; 98(24):13884-13888.
8. Pop C, Timmer J, Salvesen S. The Apoptosome Activates Caspase-9 by Dimerisation. Mol Cell 2006; 22(2): 269-275.
9. Apoptosis in unicellular organisms: mechanisms and evolution. Biochemistry 2004; 69 (10): 1301 – 1313.
10. Kummoona R, Sami S M, Al-Kapptan I, Al-Muala H. Study of antiapoptotic gene of oral carcinoma by using Bcl- 2 oncogene. Journal of Oral Pathology and Medicine 2008; 37 (6):345-351.
11. Ataman OU, Bentzen SM, Wilson GD. Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer. Eur J Cancer 2004; 40(18): 2734-2741.
12. Tupitsyn NN. Hematogenously disseminating operable cancer as a principal problem of oncology. Immunological tumor staging. Haematopoiesis Immunology 2007; 4(2): 7- 14.
13. Liang XH, Levis J, Foote R, Smith D, Kademani D. Prevalence and significance of human papillomavirus in oral tongue cancer: the Mayo clinic experience. J Oral Maxillofac Surg 2008; 66(9):1875- 1880.
14. Romanitan M, Ramquist T, Dahlstrand H, Polikretis L, et al. Human papillomavirus frequency in oral and oropharyngeal cancer in Greece. Anticancer Res.2008; 28: 2077-2080. 15.Rohde S, Kovacs B, Turowski B, et al. Intra-arterial high-dose chemotherapy with Cisplatin as part of a palliative treatment concept in oral cancer. American Journal of Neuroradiology 2005; 26:1804-1809.
16. Kovacs AF. Intraarterial chemotherapy and chemoembolization in head and neck cancer. Establishment as a neoadjuvant routine method. Cancer Ther 2003a; 1:1- 9.
17.Robbins KT, Kumar P, Harris J, et al. Supradose intraarterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: Results of Radiation Therapy. Oncology Group trial 9615. J Clin Oncol 2005; 23:1447-1454.
18. Fuwa N, Kodaira I, Furutani K, et al. Intra-arterial chemoradiotherapy for locally advanced oral cavity cancer: Analysis of therapeutic results in 134 cases. Br J Cancer 2008; 98:1039-1045.
19. Tegeder I, Brautigam L, Seegel M, et al. Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer. Clin Pharmacol Ther 2003; 73: 417-426.
20. Fuwa N., Kodaira T, Furutani K, et al Chemoradiation therapy using radiotherapy, systemic chemotherapy with 5-fluorouracil and nedaplatin and intra-arterial infusion of carboplatin for locally advanced head and neck cancer - Phase II study. Oral Oncol 2007; 43(10):1014-1020.
21. Tannock I F, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 22(11): 2233-2239.
22. Ikushima I, Kogori Y, Ishii A, et al. Superselective arterial infusion for squamous cell carcinomas of oral cavity: Histopathologic effects on metastasis neck lymph nodes. Eur Arch Otorhinolaryngol 2007; 264:269-275.
23. Gahan P.B. Circulating DNA. Intracellular and intraorgan messenger? Ann NY Acad Sci 2006; 1075: 21- 33.
24. Gormally E, Caboux P, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance. Mutat Res 2007; 635(2-3):105-117.
25. Sykes SM, Mellert HS, Holbert MA, et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 2006; 24: 841-851.
26. Rixe O, Fojo T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin Cancer Res 2007; 13:7280-7287.
27. Halazonetis TD, Gorgoulis V., Bartek J. An oncogene-induced DNA damage mode for cancer development. Science 2008; 319(5868): 1352-1355.
28. Sainger RN, Shah MN, Desai AA, Shukla SN, et al. Clinical significance of serum p53 antibodies in oral cancer. Tumori 2006; 92(2):134- 139.
29. Yamazaki Y, Chiba I, Ishikawa M, Satoh Ch, Notani K. Serum p53 antibodies as a prognostic indicator in oral squamous cell carcinoma. Odontology 2008; 96(1):32- 37.
30. Napenas JJ, Brennan MT, Fox PS. Diagnosis and treatment of xerostomia (dry mouth). Odontology 2009; 97(2):76-83.
Int J Biomed. 2010;1(1):32-37. © 2010 International Medical Research and Development Corporation. All rights reserved.
